We have previously shown that intravesical administration of adenovirus encoding human interferon a-2b (Ad-IFN) induced a marked regression of superficial human bladder tumors derived from cells that are resistant to over 1 million units/ml of IFNa protein in vitro. In addition, Ad-IFN appeared to produce strong bystander effects. In this study, we show that Ad-IFN causes marked inhibition of cell growth and apoptosis in cells of various tumor types, all of which are resistant to IFNa protein. In addition, strong perinuclear IFN staining was seen in all cell lines following Ad-IFN transfection and was never observed after exposure to the IFN protein. Ad-IFN induced proteolytic processing of caspases 3, 8 and 9, indicative of enzymatic activation. However, the caspase-8-selective inhibitor, IETDfmk, blocked apoptosis only in the cell lines that were sensitive to the IFNa protein and had minimal effect on Ad-IFN-induced caspase-3 or -9 processing and cell death, indicating that death receptor-independent mechanism(s) were involved in the cytotoxic effects observed for cancer cell lines resistant to the IFNa protein. Moreover, we document that a yet to be identified soluble factor(s) is responsible for causing the bystander effect observed following Ad-IFN treatment in IFN proteinresistant cancer cells.
Introduction
We have recently shown that interferon (IFN)-induced cytotoxicity in bladder cancer cell lines, which are sensitive to the human interferon a-2b protein (Intron A), is mediated largely through the autocrine production of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). 1 TRAIL induces apoptosis via engagement of death receptors 4 and/or 5 (DR4, DR5), leading to aggregation and enzymatic activation of caspase 8, the apical caspase in the pathway. 2 However, many bladder cancer cell lines are highly resistant to Intron A at a concentration of 10 000 IU/ml, which is considered appropriate for testing whether a cell line is IFN-sensitive or -resistant. 1 In parallel studies, we had been investigating the efficacy of intravesical adenoviral-mediated interferon a2b (Ad-IFN) when in the presence of the excipient, Syn3, to decrease superficial human urothelial tumors growing in the bladders of athymic mice. Marked tumor reduction was seen in these studies after two instillations of Ad-IFN/Syn3 for 1 h on consecutive days 3 or even after a single treatment. 4 These results have lead to a planned Phase I clinical trial using intravesical Ad-IFN/Syn3 for superficial bladder cancer.
Of particular interest to us was the fact that the cell line used for the in vivo efficacy studies, namely KU7, was later found to be highly sensitive to Ad-IFN treatment in culture despite the fact it was resistant to over 1 million IU/ml of Intron A. 3 This was the first indication that Ad-IFN might have a broader spectrum of cytotoxic effects than are triggered by exogenous recombinant IFNa. Further evidence for this idea was provided by the findings that Ad-IFN appeared to produce a strong bystander effect in these cells, whereas by definition IFN-resistant cells treated with Intron A did not. 3 In order to expand on these initial findings, 1, 3, 4 we examined additional bladder cancer cell lines, which had been shown previously to be resistant to Intron A 1 for their response to Ad-IFN and then extended the study to other Intron A-resistant non-bladder cancer lines, including those derived from malignancies of the lung, ovary and prostate as well as immortalized, genetically altered human urothelial cells. 5 In addition, a more in depth study was carried out to examine the mechanism(s) of the Ad-IFN produced bystander effects, including determining whether possible soluble factors and/or caspase-8 activation were involved in the observed cytotoxicity.
Materials and methods

Cell lines
The bladder cancer cell lines RT4, UM-UC2, UM-UC3, UMUC5, UM-UC7, UM-UC9 and UM-UC16, 1, 6 as well as the E6 or E7 immortalized cells, aE6-1, aE6-2, and eE7, 5 were provided by Dr Grossman at the UTMD Anderson Cancer Center. The ovarian cancer cell line, MDAH2774, prostate cancer cell line, DU145, and lung cancer cell line, H1299, were available in our lab. The cells were grown in minimal essential medium or RPMI 1640 with 10% fetal bovine serum (FBS) and incubated at 371C in 5% CO 2 and 95% air.
Reagents and adenovirus infection
Ad-b-gal and Ad-IFN were obtained from Canji Inc. (San Diego, CA). Cells were exposed to the adenoviral vector at a 50 or 100 multiplicity of infection (50-100 MOI) for 3 h in medium without serum except for the H1299 lung cancer cells where only a 5 MOI was used because of the high transfectability and adenoviral sensitivity of this cell line. The virus was then removed and complete control medium added. Transfection frequency was checked by Ad-IFN or Ad-b-gal staining in order to insure the transfection rates were comparable in different experiments. Recombinant a-2b-interferon from Canji Inc. (Intron A; Shering-Plough Corporation, Kenilworth, NJ) was reconstituted to 1 Â 10 7 IU/ml, and diluted to 1 Â 10 4 IU/ml with medium containing 10% FBS.
Treatment with caspase inhibitors
To examine whether Ad-IFN produced cytotoxicity was caspase-8 dependent, cells were treated with 25 mM of the caspase 8-specific inhibitor zIETDfmk after Ad-IFN or Intron A treatment. The zIETDfmk was purchased from Enzyme Systems Products (Livermore, CA).
Quantification of apoptosis by propidium iodide staining The cells were plated into 100-mm dishes at 1 Â 10 6 cells/ dish 24 h before infection. After Ad-IFN infection or Intron A exposure with or without the caspase inhibitors described above, the control and treated cells were harvested with trypsin-EDTA and washed in 1 ml of cold phosphate buffered saline (PBS). The cells were suspended in 0.5 ml of propidium iodide (PI) solution (50 mg/ ml PI, 0.1% Triton X-100 and 0.1% sodium citrate in water). Cells were then incubated at 41C for 2 h in the dark, and then the fluorescence was read on a Coulter Epics (R) XL (Beckman-Coulter, Brea, CA).
Use of cell inserts to examine potential soluble Ad-IFN bystander effect
The approach taken is illustrated in Figure 7a . Cell culture inserts (containing a 3.0 mm high pore density polyester membrane) designed to fit into 35-mm wells were obtained from Becton Dickinson Labware. They were placed initially in separate six-well 35-mm dishes and UC-9 cells were plated into the inserts at 1 Â 10 5 cells/per insert in 2 ml of control medium containing 10% FBS. In a second six-well dish, which did not contain an insert 1 Â 10 5 UC-9 cells/well were also plated in 2 ml of control medium containing 10% FBS. The cells in these latter wells were to be used as the bottom untreated responder or target cells. After 24 h, the cells in the first six-well plate containing the inserts and UC-9 cells were treated with Ad-IFN or Ad-b-gal and incubated at 371C for 2-4 h. The cells were then washed two times with medium and again 2 ml of control medium containing 10% FBS was added to the inserts. In some dishes, Intron A was added to the inserts with no prior Ad-IFN or Ad-b-gal treatment. Finally, the inserts containing the membrane and treated cells were transferred into the wells containing only the untreated target cells.
For studies to evaluate the possible role of TRAIL in the bystander effect, either control medium, TRAIL protein (25 ng/ml), anti-TRAIL (1 mg/ml) or TRAIL protein (25 ng/ml) þ anti-TRAIL (1 mg/ml) was added in some of the bottom wells containing the previously untreated cells. For these experiments 24 and 48 h following Ad-IFN treatment in the top inserts as outlined above, the medium was removed and concentrated with a Amicon Ultra-4 centrifugal filter device (10 000 NMWL) purchased from Millipore. Quantikine, the TRAIL ELISA Assay Kit purchased from R&D Systems Inc. (Minneapolis, MN) was then used for the TRAIL assay according to the manufacturer's instruction.
MTT assay
The various cells were seeded into 24-well plates at 4 Â 10 4 cells/well on the day before infection. The cells were infected for 2.5 h as described above. The medium was then removed at different time points, and 200 ml of medium added containing 1 mg/ml 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). After 3 h, the reaction was stopped with 200 ml of N,Ndimethylformamide lysis buffer, and the resultant solution read at A595 with a microreader.
Western blotting
The bladder cancer cell line, UC-9, was transfected with a 50 MOI of Ad-IFN with or without treatment of zIETDfmk caspase-8 inhibitor (Calbiochem, San Diego, CA) at 25 mM. After 48 and 72 h, respectively, cells were lysed in sodiumdodecyl sulfate (SDS) buffer (150 mmol/l NaCl, 1% NP40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mmol/l Tris (pH 8.0), and protease inhibitors (Roche Diagnostics, Roche Applied Science, Indianapolis, IN)), subjected to 15% SDS-PAGE, and transferred to nitrocellulose membranes. Membranes were blotted with the following antibodies: cleaved caspase-3, cleaved caspase-8 and cleaved caspase-9 (Cell Signaling Technology, Beverly, MA). Equal loading was confirmed by blotting with anti-b-Actin antibody (Sigma, St Louis, MO). The blots were incubated with chemiluminescent substrate (ECL, Amersham, Little Chalfont, UK) and then developed by exposure to X-ray film.
Immunostaining
Immunochemical analysis was performed according to previously described methods. 3 Confocal microscopy analysis for active caspase and IFNa localization Forty-eight hours postinfection, the cells were fixed in icecold methanol, blocked in PBS with 10% goat serum and incubated overnight with a mouse monoclonal antibody against IFN-a (PBL, Piscataway, NJ) diluted 1:1000 in PBS with 1% goat serum and with polyclonal rabbit antibodies against cleaved caspase-3, anti-cleaved caspase-8 and anti-cleaved caspase-9, respectively (Cell Signaling Technology, Beverly, MA), diluted 1:500. Cells were washed three times in PBS, then incubated for 1 h with an Alexa-546-labeled goat anti-mouse antibody, Alexa-488-labeled goat anti-rabbit antibody (Molecular Probes, Eugene, OR) and the DNA dye 633-Topro-3 (Molecular Probes). Digital micrographs were acquired using serial laser excitation on an Olympus FV300 laser scanning confocal microscope, and then were imported into a Dell Power Edge 2200 computer for processing using the Lasersharp 3.0 program (Bio-Rad). In order to get rid of the background noise, signal thresholds were set up according to corresponding control slides. Selected images are representative of at least 10 microscopic fields analyzed for each condition.
Statistical analysis
For the MTT and Flow results, the analysis was carried out using the General Lineal Models of the Statistica software (StatSoft Inc., Tulsa, OK).
Results
Ad-IFN inhibits cell growth and is cytotoxic to Intron A-resistant bladder and non-bladder cancer cell lines
Although the bladder cancer cell lines UM-UC2, UM-UC3, UM-UC5, UM-UC7, UM-UC9 and UM-UC16 were found to be resistant to as much as 1 million units/ml of Intron A (1, 3 and data not shown), all cell lines underwent growth inhibition when exposed to a 100 MOI of Ad-IFNa ( Figure 1 ) as well as variable amounts of apoptosis as measured by PI staining and flow cytometry (PI/fluorescence-activated cell sorting (FACS)). Ad-b-gal (100 MOI) was used as a control and had little or no effect on cell viability.
To investigate whether or not the observed effects of Ad-IFN were bladder cancer-specific, we examined several other tumor types to identify examples of cell lines that were resistant to Intron A. Intron A-resistant cell lines were easily identified and included the DU145 prostate cancer, H1299 lung cancer and MDAH2274 ovarian cancer cells. A similar high cytotoxicity to Ad-IFN was found as was observed for bladder cancer cell lines, whereas little if any growth inhibition was seen after treatment with 10 000 IU/ml of Intron A for 24-96 h or a 100 MOI of Ad-b-gal ( Figure 2) . A concentration of 10 000 IU/ml of Intron A is considered to be adequate for determining sensitivity or resistance to the interferon protein.
1 For H1299 lung cancer cells, an MOI of 5 for both Ad-IFN and Ad-b-gal was used because of the sensitivity of these cells to adenoviral transfection.
Bladder cancer cells, which are sensitive to IFN protein (Intron A), are killed primarily through a TRAIL-related mechanism, and in such cells IFN-induced apoptosis is completely blocked by the caspase 8-selective inhibitor zIETDfmk. 1 This effect can be seen within 24-48 h after exposure. 1 The RT4 superficial bladder cancer cell line is representative of these IFN protein-sensitive cell lines. We also found that Ad-IFN-induced apoptosis was completely blocked by zIETDfmk in RT4 cells as measured by PI/FACS (Figure 3 We extended these observations by directly assessing the proteolytic processing of caspases 3, 8 and 9. As shown in Figure 4 , Intron A had little or no effect on caspase-3, -8 or -9 activation, confirming the conclusion derived from the PI/FACS results that these cells are resistant to IFNa-induced apoptosis. In contrast, marked processing of caspase-3, -8 and -9 was seen after Ad-IFN treatment. Importantly, although Ad-IFNinduced caspase-8 activation was completely blocked by zIETDfmk, the inhibitor had little or no effect on activation of caspases-3 and -9. These data are consistent with the PI/FACS results and strongly suggest that Ad-IFN engages the mitochondrial pathway of apoptosis via a mechanism that is independent of caspase-8 activation.
The caspase-3, -8 and -9 cleavage status in attached cells 48 h after Ad-IFN or Ad-IFN þ IETD treatment is also shown in Figure 5 . Cleaved caspase-3 and -9 was seen in IFN-expressing and nonexpressing cells after either Ad-IFN or Ad-IFN þ IETD treatment, indicating that Ad-IFN produced apoptosis not only in Ad-IFN-expressing cells but also in cells that were not transduced by Ad-IFN, again indicative of a strong bystander effect. In contrast, although caspase 8 cleavage was observed in both IFNpositive and IFN-negative cells after Ad-IFN treatment, it was completely blocked in Ad-IFN þ IETD-treated cells ( Figure 5 ). However, as mentioned above and shown in Figures 3 and 4a , IETDfmk had little or no effect on Ad-IFN-induced apoptosis (PI/FACS) or growth inhibition assays (MTT), suggesting that the bystander effects of Ad-IFN are mediated via a caspase 8-independent mechanism. Of interest, similar inhibition of cell growth, apoptosis and morphological changes as well as perinuclear IFN staining was produced by Ad-IFN in E6 and E7 genetically altered, immortalized but not tumorigenic human urothelial cell lines (not shown).
Ad-IFN produces bystander effects, which are mediated by soluble factor(s) We subsequently investigated whether or not a soluble factor(s) was involved in mediating the Ad-IFN-induced bystander effects using an insert co-culture method. UC-9 cells were placed in the upper and lower wells of plates, with the upper well containing a 3.0 mm high-density polyester membrane (Figure 7a ). The cells in the upper wells were treated with Ad-IFN or Ad-b-gal, as outlined in the Materials and methods. The untreated cells in the lower wells (target cells) were observed for any changes using a phase microscope. Many cells in the bottom wells displayed morphological characteristics typical of apoptosis 24 h after cells in the upper wells had been transduced with Ad-IFN. In contrast, no such changes were observed in cells transduced with Ad-b-gal. By 48 h after treatment, many floating cells were observed in the bottom wells when the upper wells containing the membrane were exposed to Ad-IFN (Figure 7b2 and b4) . Approximately 50% of the cells were found to be apoptotic, that is, to be in the SubG1 fraction by FACs analysis demonstrating a strong bystander effect (not shown).
Of particular interest, none of the target cells in the bottom dishes showed any morphological changes characteristic of Ad-IFN expression. Moreover, when coverslips were placed in parallel dishes and stained for IFN, no cells were found that were IFN-positive in the bottom wells (Figure 7c, bottom well) . However, typical IFN staining was found in the cells that had been infected with Ad-IFN in the top well above the membrane (Figure 7c , top well). This confirmed that the cell kill was induced via Ad-IFN overcomes IFN protein resistance via bystander effects X Zhang et al a factor or factors produced in the Ad-IFN-transfected cells in the top well and transferred to the medium which caused the cell death in the bottom target cells, rather than passage of Ad-IFN through the filters and subsequent transduction of the cells in the lower chambers.
As the UC9 cells are resistant to over 1 million units of Intron A, the IFN produced by the Ad-IFN-treated cells in the top wells, which was subsequently transferred into the bottom wells could not be a component of the soluble factor(s) causing the bystander effects. In fact, under these conditions, only approximately 1000 U of IFN/ml were produced over a 48 h time period in either the top or bottom well supernatant by ELISA (data not shown).
We also measured TRAIL expression in UC-9 cells exposed to IFNa or Ad-IFN by ELISA. Although recombinant IFNa did induce an increase in TRAIL expression in the cells, TRAIL levels in cells transduced by Ad-IFN were lower than that observed in controls. In addition, neither IETDfmk nor a blocking anti-TRAIL antibody had any effect on Ad-IFN-induced bystander killing, although they completely neutralized cell death induced by exogenous recombinant TRAIL (data not shown). Together, these results confirm that the Ad-IFNinduced bystander effect is mediated by soluble factor(s) that induce apoptosis via TRAIL-and caspase 8-independent mechanisms.
Discussion
We initially reported that intravesical instillation of Ad-IFN in the presence of the excipient, Syn3, which significantly increases adenoviral-mediated gene transfer, 7, 8 produced a marked reduction in human bladder tumors growing superficially in the bladder of athymic mice. 3 A Phase l clinical trial is now planned based largely on these results. As mentioned above, it was surprising to find that the cell line used for this in vivo study (KU-7) was highly resistant to Intron A, 3 an observation that served as the foundation of our concept that Ad-IFN produces a broader spectrum of cytotoxic effects than Intron A itself.
One purpose of this study was to directly test our concept in a larger panel of human bladder cancer cell lines as well as cells derived from other malignancies. Figure 5 The presence of cleaved caspase-3, -8 and -9 in Ad-IFN-expressing and -non-expressing cells. Cleaved caspase-3, -8 and -9 (green) are seen in both IFN-expressing (red) -and non-expressing cells 48 h after Ad-IFN treatment. IETD completely blocked caspase-8 cleavage, whereas it had no effect on caspase-3 or caspase-9 cleavage as predicted. used 10 000 IU/ml of Intron A to determine whether or not a cell line was resistant to Intron A. Although it is generally agreed that this is an adequate concentration to test IFN resistance, we have used up to 100 000 IU/ml of Intron A without finding any cytotoxicity. Another unique property of Ad-IFN we have found is the strong perinuclear IFN staining pattern following transduction with Ad-IFN, whereas no IFN staining is seen after Intron A exposure. These IFN-expressing cells display caspase-3, -8 and -9 cleavage as shown by immunoblotting ( Figure 4 ) and confocal microscopy ( Figure 5 ). However, although caspase-8 cleavage is found in Ad-IFN-treated cells, the caspase-8 inhibitor, zIEDT, has no effect on Ad-IFN-mediated cytotoxicity in cells that are resistant to the recombinant IFNa protein. Therefore, and in constrast to cell death induced by either recombinant IFNa 1 or TRAIL in IFN-sensitive cells, a caspase 8-dependent mechanism does not appear to contribute substantially to apoptosis induced by Ad-IFN in IFNa-resistant cells.
Another purpose of this study was to further examine the bystander effect produced by Ad-IFN in cell culture. The first indication that Ad-IFN had strong bystander effects was the finding in the IFN-resistant bladder cancer cell lines, KU-7 and BV, that Ad-IFN also killed cells that were adjacent to those transduced with Ad-IFN as well as the Ad-IFN-transfected cells themselves. 3 We have now shown in the IFN-resistant cell line, UC-9, that a soluble factor(s) is produced by the Ad-IFN-expressing cells which is responsible for much of the bystander effects in IFN-resistant cancer cells and is not TRAIL related. We have subsequently found similar results for other IFNresistant cancer cell lines (data not shown). As the UC-9 cells are resistant to over 1 million units of IFN/ml in cell culture, the production of IFN following Ad-IFN treatment cannot be a factor in the bystander effect observed. In addition, we have found that only approximately 1000 U of IFN is secreted into the medium over the period of the experiment under parallel conditions with the number of cells plated (1 Â 10 5 ). As also mentioned above, human Ad-IFNa had marked antitumor activity in the human KU7 cells growing as superficial bladder tumors in mice when injected intravesically. 3 It should be noted that in this study a hybrid Ad-IFN, which is effective against both human and mouse cells, had no greater antitumor effect on Ad-IFN which is human specific, 3 indicating that a host bystander effect did not contribute significantly to Ad-IFN overcomes IFN protein resistance via bystander effects X Zhang et al the tumor cell kill in our in vivo studies. We would postulate that the actual soluble factor(s) we have found to produce a bystander effect in vitro may be responsible for a considerable amount of that antitumor activity seen following intravesical Ad-IFN treatment. These findings could have particular relevance in the outcome of our planned clinical trials. The identification of the soluble factor(s), which is producing the bystander effect observed could also be important for practical purposes, as there is a possibility that it might have therapeutic efficacy itself. Ad-IFN overcomes IFN protein resistance via bystander effects X Zhang et al
